Chinese Scientist Unite Together to Tackle With COVID-19

Science and Technology Daily

Chinese Scientist Unite Together to Tackle With COVID-19

PR82933

BEIJING, Feb. 19, 2020 /PRNewswire=KYODO JBN/

Reported by Science & Technology Daily:

As to the battle against the COVID-19, Chinese Ministry of Science and Technology

(MOST) has been launched the program of "Dealing With the Outbreak of COVID-19

Using Science and Technology", a program including four batches of 20 emergency

projects until now. Moreover, MOST re-examining two major scientific and technological

projects, including the "Creation of Important Innovative New Drugs" and the "Prevention

and Treatment of Severe Contagions", and a series of national essential research and

development plans. Recently, some important achievements from these projects have

already been implemented in the front line of epidemic prevention and control.

When it comes to drug screening, front-line staff from different research teams

collaborated on the basis of existing researches, making great efforts to

systematically and massively screen the drugs that have been on the market

already or already go into clinical trials. As a consequence, they discovered

potentially effective anti- coronavirus drugs, such as Chloroquine Phosphate,

Remdesivir, and Favipiravir. Furthermore, in recent days, researchers have

urgently launched some clinical trials and the results show that the curative

effect of drugs on patients is increasingly obvious.

Based on the R&D level and preliminary accumulation in the field of cell therapy,

traditional Chinese medicine and plasma therapy in China, the clinical trials of

the three therapies organized by the "Joint Prevention and Control Group" have been

gradually carried out, and they are playing significant role in curing critically ill patients.

For the purpose of providing more cutting-edge and effective solutions to the epidemic using

stem cell therapy, the leaders of the MOST went to the Innovation Institute of Stem Cell

and Regenerative Medicine of the Chinese Academy of Science to confirm their progressing.

A new cellular drug called CAStem supposed to cure COVID-19 was created, and it has already

made major progress in the experiment about the treatment of the severe acute respiratory

distress syndrome (ARDS) previously. The research team has applied for emergency approval

from China National Medical Products Administration, and it is cooperating with relevant

medical institutions. So far, the CAStem has already been approved by the Ethics Committee,

and is ongoing clinical observation and evaluation.

An emergency project titled "Clinical Study on the Prevention and Treatment of COVID-19

by Integrated Chinese and Western Medicine" was officially launched on February 3 with

the support from the MOST. "The positive curative effect has been shown in treating COVID-19,"

said Zhang Boli, the project leader and the headmaster of Tianjin University of Traditional

Chinese Medicine. It was reported that a total of 23 patients had been cured and discharged

from Hubei Provincial Hospital of Integrated Traditional and Western Medicine and Wuhan

Hospital of Traditional Chinese Medicine.

With regard to the field of plasma therapy, China National Biotech Group has

completed the collection of plasma from some convalescent patients, as well as

the preparation of special immune plasma products and special immune globulin

of novel coronavirus on February 13. Through strict blood biosafety testing,

virus inactivation, and antiviral activity testing, etc., special immune plasma

has been successfully prepared for clinical treatment and has already been put

into clinical treatment of severely ill patients.

In terms of field of vaccine research and development, the Chinese Center for

Disease Control and Prevention (CDC) had successfully isolated the first

COVID-19 virus strain on January 24, which was recognized by the World Health

Organization and other international agencies. Several new type of vaccines for

COVID-19 have started the animal testing phase, which bring hope to all.

SOURCE: Science and Technology Daily

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中